|
rs12744757
|
CLCN6;NPPA;NPPA-AS1
|
Systolic Pressure
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Novel Blood Pressure Locus and Gene Discovery Using Genome-Wide Association Study and Expression Data Sets From Blood and the Kidney.
|
28739976 |
2017 |
|
rs202102042
|
CLCN6;NPPA;NPPA-AS1
|
Systolic Pressure
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Trans-ethnic association study of blood pressure determinants in over 750,000 individuals.
|
30578418 |
2019 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Systolic Pressure
|
|
0.700 |
GeneticVariation |
GWASCAT |
A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure.
|
29455858 |
2018 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Stable angina
|
|
0.010 |
GeneticVariation |
BEFREE |
Cox proportional hazard analysis tested by 4 models confirmed higher major adverse cardiovascular events risk in rs5065 MA carriers in both SA and rSA cohorts.
|
22575314 |
2012 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Psoriasis
|
|
0.700 |
GeneticVariation |
GWASCAT |
Whole-exome SNP array identifies 15 new susceptibility loci for psoriasis.
|
25854761 |
2015 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Obesity
|
|
0.010 |
GeneticVariation |
BEFREE |
In whites, the minor G allele of the atrial natriuretic peptide (ANP) genetic variant rs5068 is associated with higher circulating levels of ANP and B-type natriuretic peptide (BNP), lower risk of hypertension, higher high-density lipoprotein (HDL) cholesterol plasma levels, and lower prevalence of obesity and metabolic syndrome.
|
29253899 |
2017 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Multiple Chronic Conditions
|
|
0.010 |
GeneticVariation |
BEFREE |
A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA).
|
29253899 |
2017 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Metabolic Syndrome X
|
|
0.010 |
GeneticVariation |
BEFREE |
The rs5068 AG+GG genotypes are associated with lower prevalence of metabolic syndrome and lower triglycerides values.
|
29253899 |
2017 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Left Ventricular Hypertrophy
|
|
0.010 |
GeneticVariation |
BEFREE |
These findings suggest that rs5068, or genetic variants in linkage disequilibrium, might affect susceptibility to left ventricular hypertrophy and support the possible protective role of natriuretic peptides.
|
23799939 |
2013 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Hypotension, Orthostatic
|
|
0.010 |
GeneticVariation |
BEFREE |
Among subjects not taking BP-lowering drugs, three SNPs within the NPPA/NPPB locus were nominally associated with increased risk of OH (rs17367504: 1.13, 1.02-1.24; P = 0.02, rs198358: 1.10, 1.01-1.20; P = 0.04, and rs5068: 1.22, 1.04-1.43; P = 0.01).
|
22504314 |
2012 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.060 |
GeneticVariation |
BEFREE |
Carriers of rs5063 had lower NT-proANP levels (1427 versus 2291 pmol/L; P<0.001) and higher diastolic blood pressures (75 versus 73 mm Hg; P=0.009) and were at an increased risk of stroke when compared with wild-type subjects independent of age, sex, diabetes mellitus, hypertension, atrial fibrillation, and cholesterol levels (hazard ratio, 1.6; P=0.004).
|
25452597 |
2015 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.060 |
GeneticVariation |
BEFREE |
Two common single nucleotide polymorphisms (SNPs) in NPPA, rs5063 and rs5065, result in amino acid changes of the primary peptide and have been previously implicated in conditions associated with AF, including stroke and hypertension.
|
20543198 |
2010 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.060 |
GeneticVariation |
BEFREE |
Hazard ratios (95% CIs) for incident hypertension were 0.88 (0.80 to 0.96; P=0.005) for the rs5063 variant and 0.95 (0.90 to 1.00; P=0.068) for the rs5065 variant.
|
17984371 |
2007 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.060 |
GeneticVariation |
BEFREE |
After adjusting for age, sex, BMI and hypertension status by logistic regression analysis, we found that NPPA rs5063 was significantly associated with both ischemic stroke (odds ratio [OR] 0.69; 95% confidence interval [CI], 0.52 to 0.90; P = 0.006) and cerebral hemorrhage(OR = 0.39; 95%CI, 0.19 to 0.78; P = 0.007).
|
25144711 |
2014 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.060 |
GeneticVariation |
BEFREE |
The findings suggested that a common NPPA SNPs rs5063 was associated with serum ANP levels and ANP was prospectively associated with hypertension in the Chinese Han population.
|
31341238 |
2019 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.060 |
GeneticVariation |
BEFREE |
This study examined the SNPs AGT rs699 (Met235Thr), ADD1 rs4961 (Gly460Trp), NPPA rs5063 (Val32Met), GPX1 rs1050450 (Pro198Leu), and AGTR1 rs5186 (A1166C) in relation to hypertension and salt sensitivity.
|
27480094 |
2017 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.030 |
GeneticVariation |
BEFREE |
Hazard ratios (95% CIs) for incident hypertension were 0.88 (0.80 to 0.96; P=0.005) for the rs5063 variant and 0.95 (0.90 to 1.00; P=0.068) for the rs5065 variant.
|
17984371 |
2007 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.030 |
GeneticVariation |
BEFREE |
Two common single nucleotide polymorphisms (SNPs) in NPPA, rs5063 and rs5065, result in amino acid changes of the primary peptide and have been previously implicated in conditions associated with AF, including stroke and hypertension.
|
20543198 |
2010 |
|
rs5065
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.030 |
GeneticVariation |
BEFREE |
Minor alleles of NPPA rs5068, rs5065 and rs198358 were associated with less history of hypertension; minor alleles of NPPA rs5068 and rs198358 was also associated with higher circulating natriuretic peptide levels (p=0.003 to p=0.04).
|
21276798 |
2011 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.030 |
GeneticVariation |
BEFREE |
In 29,717 individuals, the alleles of rs5068 and rs198358 that showed association with increased circulating natriuretic peptide concentrations were also found to be associated with lower systolic (P = 2 x 10(-6) and 6 x 10(-5), respectively) and diastolic blood pressure (P = 1 x 10(-6) and 5 x 10(-5)), as well as reduced odds of hypertension (OR = 0.85, 95% CI = 0.79-0.92, P = 4 x 10(-5); OR = 0.90, 95% CI = 0.85-0.95, P = 2 x 10(-4), respectively).
|
19219041 |
2009 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.030 |
GeneticVariation |
BEFREE |
Minor alleles of NPPA rs5068, rs5065 and rs198358 were associated with less history of hypertension; minor alleles of NPPA rs5068 and rs198358 was also associated with higher circulating natriuretic peptide levels (p=0.003 to p=0.04).
|
21276798 |
2011 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Hypertensive disease
|
|
0.030 |
GeneticVariation |
BEFREE |
In whites, the minor G allele of the atrial natriuretic peptide (ANP) genetic variant rs5068 is associated with higher circulating levels of ANP and B-type natriuretic peptide (BNP), lower risk of hypertension, higher high-density lipoprotein (HDL) cholesterol plasma levels, and lower prevalence of obesity and metabolic syndrome.
|
29253899 |
2017 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Hyperlipoproteinemia Type IIa
|
|
0.010 |
GeneticVariation |
BEFREE |
Transition T2238C, which leads to ANP with two additional arginines, and G664A (Val7Met) were investigated with lipid values and clinical phenotype in 83 FH patients.
|
16721833 |
2006 |
|
rs5063
|
CLCN6;NPPA;NPPA-AS1
|
Hypercholesterolemia, Familial
|
|
0.010 |
GeneticVariation |
BEFREE |
Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia.
|
16721833 |
2006 |
|
rs5068
|
CLCN6;NPPA;NPPA-AS1
|
Heart failure
|
|
0.010 |
GeneticVariation |
BEFREE |
There was no significant association between genotypes of rs198389, rs5068, and rs198358 and heart failure risk.
|
23315043 |
2013 |